CMX Research Inc. is a Site Management Organization (SMO), professionally and effectively conducting pharmaceutical, biotech and medical device research at our 50 sites in Canada. Our Services cover a broad range of study conduct activities that meet FDA, HPB and ICH standards. Our research efforts are segmented into clinical specialties to better serve our clients. Our commitment is to ethically, effectively and efficiently conduct medical research.

At CMX Research, we set our sights high. We know that our clients’ success depends on accurate and reliable data. We understand that you need a responsive clinical team, experienced in pharmaceutical, medical device and biotech studies.

We recognize the importance of a good enrollment rate and an interested, compliant patient population, drawn from a diversified demographic area. We recognize that time is of the essence in the work we do and we pride ourselves with our track record in patient recruitment and compliance.

CMX Research Inc. delivers the excellence you demand.

Our clinical specialties include:

• Cardiology
• Dermatology
• Endocrinology

  - Diabetes Mellitus, Type 1 and Type 2 - Osteoporosis - Dyslipidemica - Pituitary Tumors - Hirsutism

  - Thyroid Disorders - Obesity - Hypogonadism - Hypertension

• Family Practice

  - Anxiety - Arthritis - Birth Control - Communicable Diseases - Depression - Eating Disorders - Hyperlipidemia - Hypertension

  - Infectious Disease - Infections of ear, nose, throat - Preventative Medicine - Rheumatoid Arthritis - Sexually Transmitted Disease - Skin disorders - Upper and Lower Respiratory Tract Infection - Urinary Tract Infection

• Gastroenterology
• General Surgery
• Internal Medicine
• Oncology
• Orthopedics
• Pain Management
• Female Sexual Medicine
  - Menopause
  - Sexual Dysfunction
• Male Sexual Medicine

  - Andropause - Erectile Dysfunction - Hypogonadism

  - Peyronies Disease - Premature Ejaculation

• Respiratory Medicine
• Urology

  - Bladder Cancer - Kidney Cancer - Prostate Cancer - Urinary Incontinence - Erectile Dysfunction - Urinary Tract Infection

  - Prostatic Infection - Benign Prostatic Hyperplasia - Enuresis - Interstitial Cystitis - Bladder Stone - Kidney Stone

Pharmaceutical Companies

• Abbott Laboratories Limited
• Alcon Pharmaceuticals (P) Ltd.
• Amersham Biosciences
• Amgen Inc.
• AstraZeneca Pharma Inc.
• Baxter Corporation
• Bayer Inc.
• Bioniche Life Sciences Inc.
• Bristol Myers Squibb Canada Inc.
• Cellegy Pharmaceuticals Inc.
• Draxis Health Inc.
• Eli Lilly Inc.
• Ferring Pharmaceuticals
• GlaxoSmithKline
• Hoffman-Laroche Limited
• Janssen-Ortho Inc.
• MacroChem Corporation
• Novartis Pharmaceuticals Canada Inc.
• Pfizer Canada Inc.
• Procter & Gamble
• Pharmaceuticals Canada Inc.
• Purdue Pharma
• Q-Med, Inc.
• Sanofi-Aventis
• Sanofi-Aventis Canada Inc.
• Solvay Pharma Inc.
• TAP Pharmaceutical Products Inc.
• Vaxis Therapeutics Corporation
• Viropharma Incorporated
• YM Biosciences
• Wyeth-Ayerst Canada Inc.

Contract Research Organizations

• ClinTrials Research Inc.
• Covance
• Innovus Research Inc.
• Integrated Research Inc.
• MDS Clinical Trials Labs
• Omnicare, Inc.
• Parexel
• Quintiles
• Theradex

Other

• American Medical Systems
• Capnia, Incorporated
• Diagnocure Inc.
• Endocare, Inc.
• Focus Surgery
• National Cancer Institute of Canada-Clinical Trials Group
• Canada-Clinical Trials Group
• Q-Med, Inc.
• Uromed Corporation
• Vysis, Inc.

Each of the CMX Research sites is integrated into our investigators’ clinical practices. As such, they offer an attractive setting, close to public transport. Each site has been selected to ensure ready access to clinical laboratory and diagnostic imaging capabilities as well as other equipment relevant to their particular specialties. All sites also understand that, as partners in clinical development with our sponsors, we are part of a team and we pride ourselves in working in a professional and courteous manner.

CMX Research INC.

NETWORK SITES - GENERAL PRACTITIONERS = 10

NETWORK SITES - UROLOGY = 35

We are also closely affiliated with P.I.’s in the following therapeutic areas:

• Endocrinology
• Dermatology
• Nephrology
• Ophthalmology
• Rheumatology
• Pain Management
• VaccinesM

Our President and Medical Director

Dr. Richard Casey, M.D., F.R.C.S. (C), is the founder and Medical Director of CMX Research Inc. and The Male Health Centres, a treatment network offering comprehensive services in sexual medicine and prostate disorders for men. He and his professional team have participated in numerous clinical research trials and have extended their organization to include a variety of medical specialties. Dr. Casey contributes his considerable expertise and a progressive leadership style to the on-going research effort in medical therapeutics.

To find out more about Dr. Richard Casey, click here.

Vice President, Corporate Development

Dr. Jack Barkin, MD, FRCS(C), FICS, FACS, DABU, is the Urologist in Chief at the Humber River Regional Hospital, the Director of The Male Health Centre in Toronto and sits on the Faculty in the Division of Urology at the University of Toronto. Dr. Barkin facilitates new and ongoing business development opportunities in diagnostics and in Phase II - III clinical trials.

Vice President, Clinical Services

Ms. Vilija Rasutis received her Bachelor of Science in Nursing from Chicago, IL as well as a B.A degree in LTC from Athabasca, Alberta. Vilija has worked in the clinical trial business for 15 years both in acute care and community focused research settings. She oversees the daily operations of CMX Research Inc., and is responsible for managing corporate business development efforts, business modeling, proposal development and contract management. Vilija is committed to supporting industry partnerships through new initiatives such as the recently launched “Global Research Coordinator Placement” service which provides highly trained and skilled CRCs to sites. Emphasis in business modeling is on continuity and excellence in research.

Vice President, Contract Research Services

Carlo Mendoza holds a Bachelor of Science in Pharmacology. His immersion and involvement in clinical research has spanned over 15 years. He began his career as a clinical research associate at Purdue Frederick monitoring cancer pain and asthma protocols before joining GlaxoSmithKline as a study team leader managing a portfolio of clinical studies in urology, endocrinology, anaesthesiology and respirology. He later moved to Endpoint Research as a project director. Carlo currently heads the CRO division of CMX and is responsible for the execution of a broad range of contract research services including recruitment enhancement (e.g., centralized advertising and call centre pre-screening) and the implementation of investigator-led trials (grant proposals, protocol and CRF design, project management, site monitoring, data analysis and reporting).

Network Administrator

As CMX Research Network Administrator, Shelagh Saunders co-ordinates site surveys, site payments and other administrative tasks.

CMX Research sites draw patients from both our investigators own clinical practices and the local surrounding populations. Currently our total site direct patient population exceeds 200,000 with an additional 3.5 million patients within 20 miles of our sites. Canada has a tremendously varied ethic background in our population and we can offer a truly homogeneous pool of participants to draw from.

We will deliver quality service that goes beyond expectations.

CMX Commitments

• an extensive network of research sites
• a proven track record of high enrollment and patient compliance
• variety in patient demographics
• a willingness to tackle even the most challenging projects

CMX Research delivers a full range of cost-effective facilities and services.

We commit to:

• Expert principal investigators
• Efficient patient pre-screening by trained clinical staff
• Rapid patient enrollment and retention
• Immediate response to study queries
• A menu of diagnostic imaging resources
• Excellence in patient care
• Expert research sites and staff

We are continuously refining our Standard Operating Procedures to reflect exacting expectations in meeting regulatory requirements of HPB, FDA and ICH.

CMX Research Inc. is committed to:

• an on-going strategy for network site expansion
• a rigorous program of new site pre-qualification
• an on-going commitment to education and training
• stringent clinical practices

For more information, please contact:

CMX Research Inc.
416 North Service Road East, Suite 2
Oakville, ON L6H 5R2 Canada
Phone: 905-338-1078
Fax: 905-338-0054